Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer

Sedef Iskit, Cor Lieftink, Pasi Halonen, Aida Shahrabi, Patricia A. Possik, Roderick L. Beijersbergen, Daniel S. Peeper

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)42859-42872
JournalOncotarget
Volume7
Issue number28
DOIs
Publication statusPublished - 12 Jul 2016

Cite this